At #CVIT2023, I was asked to identify the most influential EuroIntervention papers in 2022 and in the first part of 2023. Since I like them all, I used the Altmetric score to be more objective, and I ordered them from position 15 to 1. A topic dominates clearly: bifurcation PCI.

Love 🎢 roller coasters except in the coronaries. #radialfirst 🏒 guide. Wire crossed but couldn’t deliver equipment

I’ve been asked to comment about the recent meta analysis of iFR compared with FFR with regards to outcome. A 🧵

Check out the expert consensus from the European Bifurcation Club and #EuroCTO Club on CTO and bifurcation lesions in this #JACCINT state-of-the-art review: bit.ly/3EAG9Bc #CardioTwitter Goran Stankovic, MD, PhD JL Gutiérrez-Chico

💥AMIODARONE is a class III antiarrhythmic drug which is widely used in ER for treating arrhythmias. A 🧵 on situations where blind use of amiodarone in emergency can be counterproductive ⚠️⚠️⚠️ With alternate therapeutic options Read on...👇 #MedTwitter #MedEd #MedX

Beware of coronary artery dissection when testing for vasospasm with acetylcholine bit.ly/3rNcVfl #EHJCaseReports Erik Rafflenbeul Aaysha Cader A.Nazmi Calik Tee Joo YEO Farhana Philipp Sommer EHJCaseReports Editor-in-Chief #CardioX #radialfirst

Great #AHA23 so far: AHA Research 🥸8 Trials: 8 take aways below Read the read👇👇 1/ATRESIA: Patients with subclinical atrial fibrillation can benefit from apixaban to reduce the risk of stroke and systemic thromboembolism.

New #JACCINT coronary study evaluated the differences in the predictors of unsuccessful #PCI in first-attempt #CTO lesions of the 3 major coronary arteries compared with the J-CTO (Japanese CTO) score. bit.ly/46lSepz #ACCIntl #CardioTwitter

La prima volta allo Stadium in occasione della foto della squadra. Iniziò tutto da qui. Iniziò dal gruppo. 🤍🖤

Can we clear arterial atherosclerotic plaques? The ACC.24 Late-Breaking Clinical Trials have been announced. My highlight is the large, phase 3, multicenter, double-blind, randomized, placebo-controlled AEGIS-II trial, a study of CSL112 (apolipoprotein A-I) infusion in patients

My take on OCT Trials and where this strategy stands in the current landscape of options for PCI guidance. A thread. 1/17 #CRT2024

New 👀insights from the International #Takotsubo (InterTAK) registry! ⬆️ prevalence in ♂️, ⬆️ recognition of midventricular TTS type, & ⬆️ short-term mortality & rates of 🫀 shock in recent years bit.ly/3Xjd7jE #ESCCongress #JACC

LVOTO complicates 7% of #Takotsubo syndrome cases, increasing the risk of in-hospital adverse events like death, #heartfailure, & cardiogenic shock. Comprehensive screening of #LVOTO & tailored management are crucial for improving outcomes. bit.ly/3MqZrx1 #JACCIMG

Don't miss this ORIGINAL ARTICLE Wiley Online Library Cardiac troponin elevation and mortality in takotsubosyndrome: New insights from the international takotsuboregistry doi.org/10.1111/eci.14… ✍️Authors: See 2nd Post Below👇 Barbara Stähli Davide Di Vece CardioTomLuscher

Takotsubo #cardiomyopathy update: LV outflow tract obstruction complicates 7% of cases, increasing in-hospital serious adverse events. Comprehensive #echofirst screening & tailored management are needed. jacc.org/doi/10.1016/j.… #JACCIMG #LVOTO Davide Di Vece rodolfo citro